Welcome to our dedicated page for Checkpoint Therapeutics news (Ticker: CKPT), a resource for investors and traders seeking the latest updates and insights on Checkpoint Therapeutics stock.
This page archives news coverage for Checkpoint Therapeutics, Inc. (CKPT), a former immuno-oncology biopharmaceutical company acquired by Sun Pharmaceutical Industries in 2025. Checkpoint Therapeutics specialized in developing checkpoint inhibitor therapies and targeted treatments for solid tumor cancers before its acquisition.
Historical news coverage documents the company's clinical trial progress, regulatory milestones, and corporate developments that led to the Sun Pharma acquisition. Key news categories included clinical trial updates for drug candidates like cosibelimab (PD-L1 antibody) and CK-101 (EGFR inhibitor), financial results reporting quarterly operational progress, and strategic partnership announcements with companies like TG Therapeutics.
The news archive provides context on Checkpoint's journey as a clinical-stage biotech subsidiary of Fortress Biotech, capturing the company's efforts to advance multiple oncology candidates through phase I clinical trials. Material events covered include the acquisition announcement by Sun Pharma, quarterly financial reports detailing R&D expenditures and clinical progress, and updates on the company's pipeline development strategy.
This historical archive serves as a record of Checkpoint Therapeutics' operations in the competitive immuno-oncology sector and the developments that preceded its integration into Sun Pharma's pharmaceutical portfolio.
FAQ
What is the current stock price of Checkpoint Therapeutics (CKPT)?
What is the market cap of Checkpoint Therapeutics (CKPT)?
